CN115135644A - 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型 - Google Patents

3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型 Download PDF

Info

Publication number
CN115135644A
CN115135644A CN202180013974.1A CN202180013974A CN115135644A CN 115135644 A CN115135644 A CN 115135644A CN 202180013974 A CN202180013974 A CN 202180013974A CN 115135644 A CN115135644 A CN 115135644A
Authority
CN
China
Prior art keywords
compound
formula
degrees
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180013974.1A
Other languages
English (en)
Inventor
于娟
王友鑫
殷婷婷
曾金香
张玲玲
丁强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Leado Pharmatech Co ltd
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Original Assignee
Shanghai Leado Pharmatech Co ltd
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Leado Pharmatech Co ltd, Zhangzhou Pientzehuang Pharmaceutical Co Ltd filed Critical Shanghai Leado Pharmatech Co ltd
Publication of CN115135644A publication Critical patent/CN115135644A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

提供式I化合物、其制备方法、盐酸盐晶型A。所述的式I化合物、其盐酸盐晶型A对瞬时受体电位民通道蛋白(TPR)具有优异的抑制作用，并对瞬时受体电位通道蛋白相关的疾病具有良好的治疗作用。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180013974.1A 2020-02-14 2021-02-09 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型 Pending CN115135644A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010093694 2020-02-14
CN2020100936943 2020-02-14
PCT/CN2021/076337 WO2021160134A1 (zh) 2020-02-14 2021-02-09 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型

Publications (1)

Publication Number Publication Date
CN115135644A true CN115135644A (zh) 2022-09-30

Family

ID=77292666

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180013974.1A Pending CN115135644A (zh) 2020-02-14 2021-02-09 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型

Country Status (5)

Country Link
US (1) US20230339920A1 (zh)
EP (1) EP4105212A4 (zh)
JP (1) JP7446591B2 (zh)
CN (1) CN115135644A (zh)
WO (1) WO2021160134A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011128370A1 (en) * 2010-04-13 2011-10-20 Krka, D.D., Novo Mesto Synthesis of duloxetine and/or pharmaceutically acceptable salts thereof
CN107840845A (zh) * 2016-09-19 2018-03-27 上海璃道医药科技有限公司 胺类化合物的新用途
WO2018115069A1 (en) * 2016-12-20 2018-06-28 Laboratorios Del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
CN108947989A (zh) * 2017-05-19 2018-12-07 泰州华元医药科技有限公司 氘代光学异构体及其医药用途
CN109748914A (zh) * 2018-12-29 2019-05-14 上海珂臻医药科技有限公司 吡啶并嘧啶类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201026700A (en) 2008-12-22 2010-07-16 Hydra Biosciences Inc Compositions useful for treating disorders related to TRPA1
CN102850335B (zh) 2011-07-01 2017-02-22 石药集团中奇制药技术（石家庄）有限公司 光学异构体及其医药用途
CN107625762B (zh) * 2016-07-25 2021-11-19 上海璃道医药科技有限公司 萘环类药物的新用途
EP3339304A1 (en) 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Quinoline and isoquinoline derivatives for treating pain and pain related conditions
WO2020035040A1 (zh) * 2018-08-17 2020-02-20 上海璃道医药科技有限公司 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途
JP7283669B2 (ja) 2018-08-17 2023-05-30 チャンチョウ ピエン ツェ フアン ファーマシューティカル カンパニー リミテッド ３－アリールオキシ－３－アリール－プロピルアミン化合物およびその用途
AU2020276005B2 (en) * 2019-05-16 2023-05-18 Shanghai Leado Pharmatech Co. Ltd. 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011128370A1 (en) * 2010-04-13 2011-10-20 Krka, D.D., Novo Mesto Synthesis of duloxetine and/or pharmaceutically acceptable salts thereof
CN107840845A (zh) * 2016-09-19 2018-03-27 上海璃道医药科技有限公司 胺类化合物的新用途
WO2018115069A1 (en) * 2016-12-20 2018-06-28 Laboratorios Del Dr. Esteve, S.A. Nitrogen containing bicyclic derivatives for treating pain and pain related conditions
CN108947989A (zh) * 2017-05-19 2018-12-07 泰州华元医药科技有限公司 氘代光学异构体及其医药用途
CN109748914A (zh) * 2018-12-29 2019-05-14 上海珂臻医药科技有限公司 吡啶并嘧啶类化合物及其应用

Also Published As

Publication number Publication date
JP7446591B2 (ja) 2024-03-11
WO2021160134A1 (zh) 2021-08-19
JP2023513922A (ja) 2023-04-04
US20230339920A1 (en) 2023-10-26
EP4105212A1 (en) 2022-12-21
EP4105212A4 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
CN112566909B (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其用途
CN112654616B (zh) 3-芳氧基-3-芳香基-丙胺类化合物及其用途
SK657890A3 (en) Chroman derivative, methods for producing the same and pharmaceutical composition containing the same
KR20140099492A (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
AU2017351756B2 (en) Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders
US11834432B2 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
EP3971181A1 (en) 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof
CN111943943A (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途
JP2021523934A (ja) ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物
CN115135644A (zh) 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法及晶型
CN114149386A (zh) 芳基戊二烯酰胺类醛脱氢酶抑制剂、其合成方法及用途
CA2905950A1 (en) Novel breathing control modulating compounds, and methods of using same
CN114685292A (zh) 反式金刚烷氨衍生物或其盐的用途
JP2021505573A (ja) ベータ−２選択的アドレナリン性受容体アゴニスト
CA3140231C (en) 3-aryloxyl-3-five-membered heteroaryl-propylamine compound, and crystal form and use thereof
CN108069833B (zh) 苯并四环衍生物及其制备方法和在医药上的应用
CN114507153A (zh) 一类间苯二酚化合物及其制备方法以及在神经***疾病中的应用
CA3230557A1 (en) Ep4 antagonist compound as well as salt, polymorph, and use thereof
WO2008086678A2 (fr) Usage médical de lévophéncynonate comme agent neuroprotecteur
CN115108923A (zh) 反式金刚烷氨衍生物或其盐、及制备方法、组合物和用途
WO2021149767A1 (ja) ヘテロ環誘導体
TW202306955A (zh) 作為atr抑制劑的萘啶衍生物及其製備方法
CN111377938A (zh) 一类香豆素类衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination